X4 PHARMACEUTICALS INC (XFOR)
Health Care · Orphan drug / rare disease immunology · NASDAQ
A commercial-stage biopharmaceutical company focused on developing and marketing targeted therapies for rare immune system disorders, headlined by its FDA-approved treatment for WHIM syndrome.
What X4 PHARMACEUTICALS INC does
X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. The company's lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the FDA to increase the number of circulating mature neutrophils and lymphocytes in patients 12 years and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. X4 is currently focused on generating revenue from XOLREMDI sales and developing additional product candidates in related areas.
Themes: rare diseases, immunology, orphan drug development
Fundamentals
- Price$4.04 as of 2026-08-21 close
- Market cap$401M as of 2026-08-21
- 1-year return+27.0% 2025-08-21 close $3.18 → 2026-08-21 close $4.04
- P/En/a negative earnings
- Net margin-1106.3% as of 2026-08-24
- Gross margin+81.8% as of 2026-08-24
- ROE-94.9% as of 2026-08-24
- Debt / equity0.45 as of 2026-08-24
- Revenue growth (YoY)-71.3% as of 2026-08-24
- Beta0.42 as of 2026-08-24
- Last reported earnings2025-11-05 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How XFOR compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How X4 PHARMACEUTICALS INC looks technically
X4 PHARMACEUTICALS INC (XFOR) is trading 3.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 157 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It made a new 20-day high about 11 trading days ago. It is 16.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 3.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +3.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.07 | $4.07 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.92 | $3.92 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 157 trading days ago — a "golden cross", a bullish long-term signal | 157 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 3.0% above | +3.0% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with buyers in control | 25.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 46.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($3.99 to $4.82) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 6.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $4.83 | $4.83 |
|---|---|---|
| From the 52-week high | it is 16.4% below its 52-week high (its highest price of the past year) | -16.4% |
| Above the 52-week low | it is 64.9% above its 52-week low (its lowest price of the past year) | +64.9% |
| Below the 52-week high | it is 16.4% below its highest point of the past year | 16.4% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day high about 38 trading days ago | 38 sessions |
| All-time high | its highest closing price on record is $5206.71 (set on 2018-03-15) | $5206.71 |
| Given back of the 52-week move | over the past year its closes ranged ($2.49 to $4.67), and it has given back roughly a quarter of its rise from last year’s low — 29% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.25 to $3.32. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 28.9% |
| From the all-time high | it is 99.9% below its all-time high | -99.9% |
| Nearest price level | it is trading 3.2% above a support level at $3.91 — a price it turned at twice since 2025-11-25, most recently on 2026-06-25. Since 2024-08-21 it has 7 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.2% |
| All-time low | its lowest closing price on record is $1.35 (set on 2025-08-11) | $1.35 |
| Above the all-time low | it is 199.3% above its all-time low | +199.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 78% of it) | 22nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2524 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2524 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.83 and $4.49 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.83 – $4.16 – $4.49 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 0.5 daily ranges above its 200-day average price (3.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.76× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-08-07 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 8 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.2 percentage points (the stock gained 9.5% while the market gained 2.3%) | +7.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.1 percentage points (the stock gained 0.0% while the market gained 3.1%) | -3.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 16.8 percentage points (the stock gained 27.8% while the market gained 11.1%) | +16.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 6.6 percentage points (the stock gained 27.0% while the market gained 20.5%) | +6.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.4% of the share price, which is taken to mean a barrier that gives way easily. | -2.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.00 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +1.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $4.28 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -5.6% |
Price levels it has turned at before
XFOR last closed at $4.04 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.91 | Support | 3.2% below the last close | turned there twice · 2025-11-25 to 2026-06-25 |
| $3.69 | Support | 8.6% below the last close | turned there three times · 2025-09-23 to 2026-06-08 |
| $4.39 | Resistance | 8.7% above the last close | turned there twice · 2026-05-29 to 2026-06-22 |
| $4.51 | Resistance | 11.7% above the last close | turned there five times · 2025-06-09 to 2026-07-13 |
| $3.55 | Support | 12.0% below the last close | turned there five times · 2026-01-15 to 2026-07-22 |
| $4.63 | Resistance | 14.6% above the last close | turned there twice · 2026-04-23 to 2026-05-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · beating the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$11.60 range $10.00 – $13.00; median $12.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for XFOR
- Consensus EPS estimate-$0.186 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependence on a single commercial product, XOLREMDI, for revenue generation.","Substantial risk of ongoing operating losses and potential need for additional capital to maintain operations.","Uncertainty regarding market size, growth potential, and successful commercial adoption of its sole approved therapy."]
What changed in the latest 10-Q
AI-assisted comparison of XFOR's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
- Added:
- Newer filing (2026-05-06) includes a full 'Cautionary Note Regarding Forward-Looking Statements' section with detailed bullet points regarding risk factors, clinical development, XOLREMDI product specifics, and market acceptance
- Newer filing (2026-05-06) includes 'PART I FINANCIAL INFORMATION' with condensed consolidated balance sheets showing assets, liabilities, and stockholders' equity as of March 31, 2026 and December 31, 2025
- Newer filing (2026-05-06) references the Form 10-K for the year ended December 31, 2025 regarding risk factors discussion
- Removed:
- Older filing (2025-11-05) contained specific reference to risk factors disclosed in Form 10-Q for quarter ended June 30, 2025
- Older filing (2025-11-05) included 'Item 5. Other Information' subsection detailing Rule 10b5-1 trading plans for Dr. Paula Ragan, Adam Mostafa, and Mark Baldry with specific dates and share quantities
- Older filing (2025-11-05) included detailed exhibits list with incorporation by reference details for exhibits 3.1 through 104
- Reworded:
- Risk Factors section changed from referencing June 30, 2025 10-Q (older filing dated 2025-11-05) to referencing December 31, 2025 Form 10-K (newer filing dated 2026-05-06)
- Newer filing expands forward-looking statements section with extensive enumerated risks and uncertainties, whereas older filing provided only brief reference to general risks
- Notes:
- The provided excerpts appear to show different sections of the 10-Q filings (older filing shows Item 1A through Item 6 with exhibits; newer filing shows Item 1A header and forward-looking statements plus financial statements). The comparison is limited to overlapping content present in both excerpts
- The newer filing excerpt is truncated at the balance sheet section and does not include the full Item 5 or Item 6 sections needed for complete comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($320057) — 2 selling insiders
- Last 90 days0 buys · 3 sells ($356486) — 3 selling insiders
- Last 180 days0 buys · 4 sells ($429306) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-12. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about XFOR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding XFOR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 9,718,728
- Reported value $40,138,347
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
XFOR had 7,300,120 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
XFOR had 7.36% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.75 days to cover at the same settlement.
- Reported short interest (shares) 7,300,120
- Short interest (% of shares outstanding) 7.36%
- Prior settlement (shares) 6,501,966
- Reported change 12.28%
- Days to cover (reported) 12.75
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare XFOR vs…
X4 PHARMACEUTICALS INC is found in…
Frequently asked questions
What does X4 PHARMACEUTICALS INC (XFOR) do?
X4 Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. The company's lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the FDA to increase the number of circulating mature neutrophils and lymphocytes in patients 12 years and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome.
What sector is X4 PHARMACEUTICALS INC (XFOR) in?
X4 PHARMACEUTICALS INC (XFOR) is classified in the Health Care sector. Its industry is Orphan drug / rare disease immunology. It trades on NASDAQ.
Who are X4 PHARMACEUTICALS INC's (XFOR) competitors?
Notable peers of X4 PHARMACEUTICALS INC (XFOR) include Amgen, Gilead Sciences, Bristol Myers Squibb, Novartis and Sanofi. This peer set is informational only — not financial advice.
Is X4 PHARMACEUTICALS INC (XFOR) overbought or oversold right now?
X4 PHARMACEUTICALS INC (XFOR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on XFOR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.